|
1
|
Litzow MR: Progress and strategies for
patients with relapsed and refractory acute myeloid leukemia. Curr
Opin Hematol. 14:130–137. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cassileth PA, Harrington DP, Appelbaum FR,
Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM,
Blume KG, et al: Chemotherapy compared with autologous or
allogeneic bone marrow transplantation in the management of acute
myeloid leukemia in first remission. N Engl J Med. 339:1649–1656.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Clavio M, Carrara P, Miglino M, Pierri I,
Canepa L, Balleari E, Gatti AM, Cerri R, Celesti L, Vallebella E,
et al: High efficacy of fludarabine-containing therapy (FLAG-FLANG)
in poor risk acute myeloid leukemia. Haematologica. 81:513–520.
1996.PubMed/NCBI
|
|
4
|
Estey EH: Treatment of relapsed and
refractory acute myelogenous leukemia. Leukemia. 14:476–479. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Montillo M, Mirto S, Petti MC, Latagliata
R, Magrin S, Pinto A, Zagonel V, Mele G, Tedeschi A and Ferrara F:
Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of poor
risk acute myeloid leukemia. Am J Hematol. 58:105–109. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Byrne JL, Dasgupta E, Pallis M, Turzanski
J, Forman K, Mitchell D, Haynes AP and Russell NH: Early allogeneic
transplantation for refractory or relapsed acute leukaemia
following remission induction with FLAG. Leukemia. 13:786–791.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carella AM, Cascavilla N, Greco MM,
Melillo L, Sajeva MR, Ladogana S, D'Arena G, Perla G and Carotenuto
M: Treatment of ‘poor risk’ acute myeloid leukemia with
fludarabine, cytarabine and G-CSF (FLAG regimen): A single center
study. Leuk Lymphoma. 40:295–303. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jackson G, Taylor P, Smith GM, Marcus R,
Smith A, Chu P, Littlewood TJ, Duncombe A, Hutchinson M, Mehta AB,
et al: A multicentre, open, non-comparative phase II study of a
combination of fludarabine phosphate, cytarabine and granulocyte
colony-stimulating factor in relapsed and refractory acute myeloid
leukaemia and de novo refractory anaemia with excess of blasts in
transformation. Br J Haematol. 112:127–137. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liso V, Lacopino P, Avvisati G, Petti MC,
Broccia G, Carotenuto M, Falda M, Fazi P, Lazzarino M, Leoni P, et
al: Outcome of patients with acute myeloid leukemia who failed to
respond to a single course of first-line induction therapy: A
GIMEMA study of 218 unselected consecutive patients. Gruppo
italiano malattie ematologiche maligne dell'adulto. Leukemia.
10:1443–1452. 1996.PubMed/NCBI
|
|
10
|
Kern W, Aul C, Maschmeyer G,
Schönrock-Nabulsi R, Ludwig WD, Bartholomäus A, Bettelheim P,
Wormann B, Büchner T and Hiddemann W: Superiority of high-dose over
intermediate-dose cytosine arabinoside in the treatment of patients
with high-risk acute myeloid leukemia: Results of a age-ajusted
prospective randomized comparison. Leukemia. 12:1049–1055. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bennet JM, Catovsky D, Daniel MT, Flandrin
G, Galton DA, Gralnick HR and Sultan C: Criteria for the diagnosis
of acute leukemia of megakaryocytic lineage (M7): A report of the
French-American-British (FAB) cooperative group. Ann Intern Med.
103:460–462. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vardiman JW, Harris NL and Brunning RD:
The world health organization (WHO) classification of the myeloid
neoplasms. Blood. 100:2292–2302. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Slovak ML, Kopecky KJ, Cassileth PA,
Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR,
Rowe JM, et al: Karyotypic analysis predicts outcome of
pre-remission and post-remission therapy in adult acute myeloid
leukemia: A southwest oncology group/eastern cooperative oncology
group study. Blood. 96:4075–4083. 2000.PubMed/NCBI
|
|
14
|
Cheson BD, Bennett JM, Kopecky KJ, Büchner
T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister
TA, et al: Revised recommendations of the international working
group for diagnosis, standardization of response criteria,
treatment outcomes and reporting standards for therapeutic trials
in acute myeloid leukemia. J Clin Oncol. 21:4642–4649. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Burnett AK, Wheatley K, Goldstone AH,
Stevens RF, Hann IM, Rees JH and Harrison G: Medical Research
Council Adult and Paediatric Working Parties: The value of
allogeneic bone marrow transplant in patients with acute myeloid
leukaemia at differing risk of relapse: Results of the UK MRC AML
10 trial. Br J Haematol. 118:385–400. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pricea SL, Lancetb JE, Georgea TJ,
Wetzstein GA, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J,
Kharfan-Dabaja MA and Komrokji RS: Salvage chemotherapy regimens
for acute myeloid leukemia: Is one better? Efficacy comparison
between CLAG and MEC regimens. Leuk Res. 35:301–304. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wierzbowska1 A, Robak1 T, Pluta1 A,
Wawrzyniak E, Cebula B, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S,
Giebel S, Skotnicki AB, et al: Cladribine combined with high doses
of arabinoside cytosine, mitoxantrone and G-CSF (CLAG-M) is a
highly effective salvage regimen in patients with refractory and
relapsed acute myeloid leukemia of the poor risk: A final report of
the polish adult leukemia group. Euro J Haematol. 80:115–126. 2008.
View Article : Google Scholar
|
|
18
|
Fujimoto S and Ogawa M: Antitumor activity
of mitozantrone against murine experimental tumors: Comparative
analysis against various antitumor antibiotics. Cancer Chemother
Pharmacol. 8:157–162. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schnetzke U, Fix P, Spies-Weisshart B,
Schrenk K, Glaser A, Fricke HJ, LaRosée P, Hochhaus A and Scholl S:
Efficacy and feasibility of cyclophosphamide combined with
intermediate-dose or high-dose cytarabine for relapsed and
refractory acute myeloid leukemia (AML). J Cancer Res Clin Oncol.
140:1391–1397. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
De la Rubia J, Regadera AA, Martín G,
Cervera J, Sanz G, Martínez J, Jarque I, García I, Andreu R,
Moscardó F, et al: FLAG-IDA regimen (fludarabine, cytarabine,
idarubicin and G-CSF) in the treatment of patients with high-risk
myeloid malignancies. Leuk Res. 26:725–730. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Steinmetz HT, Schulz A, Staib P, Scheid C,
Glasmacher A, Neufang A, Franklin J, Tesch H, Diehl V and Dias
Wickramanayake P: Phase-II trial of idarubicin, fludarabine,
cytosine arabinoside and filgrastim (Ida-FLAG) for treatment of
refractory, relapsed and secondary AML. Ann Hematol. 78:418–425.
1999. View Article : Google Scholar : PubMed/NCBI
|
